42
Participants
Start Date
January 31, 2013
Primary Completion Date
April 30, 2013
Study Completion Date
April 30, 2013
Period 1
A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
Period 2
A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
Period 3
A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
Pfizer Investigational Site, Singapore
Pfizer Investigational Site, New Haven
Pfizer Investigational Site, Brussels
Lead Sponsor
Pfizer
INDUSTRY